Hydromorphone extended release - Ensysce Biosciences

Drug Profile

Hydromorphone extended release - Ensysce Biosciences

Alternative Names: ER hydromorphone - Ensysce; PF-0329; PF-329

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Pain in Australia (PO, Controlled release)
  • 22 Mar 2016 Phase I development is ongoing in Australia
  • 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top